Taxanes for adjuvant treatment of early breast cancer-Reference-Cited by-同舟云学术

Taxanes for adjuvant treatment of early breast cancer

Published:2019-09-02 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Willson Melina L¹,Burke Lucinda²,Ferguson Thomas³,Ghersi Davina⁴⁵,Nowak Anna K⁶,Wilcken Nicholas⁵⁷

Affiliation:

1. NHMRC Clinical Trials Centre, The University of Sydney; Systematic Reviews and Health Technology Assessments; Locked Bag 77 Sydney NSW Australia 1450

2. Chris O'Brien Lifehouse; Department of Radiation Oncology; Sydney Australia

3. Royal Perth Hospital; Department of Medical Oncology; Wellington St Perth WA Australia 6010

4. National Health and Medical Research Council; Research Policy and Translation; 16 Marcus Clarke Street Canberra ACT Australia 2601

5. The University of Sydney; Sydney Medical School; Sydney Australia

6. Sir Charles Gairdiner Hospital and University of Western Australia; Department of Medical Oncology; B Block, Hospital Avenue Nedlands Perth WA Australia 6099

7. Crown Princess Mary Cancer Centre; Medical Oncology; Westmead NSW Australia 2145

Publisher

Wiley

Subject

Pharmacology (medical)

Link

https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004421.pub3/epdf/full

Reference128 articles.

1. Phase III study evaluating the role of docetaxel in the adjuvant setting of breast cancer patients with ≥ 4 involved lymph nodes: ADEBAR-Study;Gauger;Journal of Clinical Oncology,2005

2. Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study;Janni;British Journal of Cancer,2016

3. Janni W Harbeck N Sommer H Rack B Augustin D Jueckstock J Randomized phase III trial of fluorouracil/epirubicin/cyclophosphamide (FEC) versus epirubicin/cyclophosphamide/docetaxel in patients with node positive primary breast cancer: final analysis of the ADEBAR study Author provided draft manuscript.

4. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel is equieffective, but less toxic than FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: the German ADEBAR phase III study;Janni;Cancer Research,2009

5. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel versus FEC120 in the adjuvant treatment of node-positive breast cancer patients: final survival analysis of the German ADEBAR phase III study;Janni;Journal of Clinical Oncology,2012

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Atrial fibrillation in cancer, anticancer therapies, and underlying mechanisms;Journal of Molecular and Cellular Cardiology;2024-09

2. 15-Year Survival Outcome of Primary Breast Conservation Therapy in Young Women with Breast Cancer;Indian Journal of Surgical Oncology;2024-08-06

3. Breast cancer treatment and its impact on survival in Morocco: a study over a decade;BMC Cancer;2024-07-01

4. Effect of Perioperative Docetaxel-induced Limb Edema on Health-related Quality of Life in Patients with Early-stage Breast Cancer: A Prospective Observational Study;YAKUGAKU ZASSHI;2024-06-01

5. Breast Cancer Immunotherapy: A Clinical Review for the Plastic Surgeon;Plastic and Reconstructive Surgery - Global Open;2024-06